Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a cholestatic liver illness that is chronic and progressive and has no known cause. PSC is characterised by inflammation, fibrosis, and/or stricturing of the intra- and/or extrahepatic biliary ducts. PSC often develops over time and might result in cholestasis and liver failure as consequences. Without a liver transplant, the median period from diagnosis to death is about ten years.
“Primary Sclerosing Cholangitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.
The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report:
Route of Administration
Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Molecule Type
Products have been categorized under various Molecule types, such as
Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
DelveInsight’s Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like
Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:
Key companies developing therapies for Primary Sclerosing Cholangitis are – Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic, Mirum Pharmaceuticals, Chemomab Therapeutics, Cascade Pharmaceuticals, Qing Bile Therapeutics, Engitix, BiomX, COUR Pharmaceutical, Avolynt, Inc., Selecta Biosciences, Gannex Pharma, LISCure Bioscience, Genfit, HighTide Therapeutics, Calliditas Therapeutics, Invea Therapeutics, and others
Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline TherapeuticAssessment-
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight
Primary Sclerosing Cholangitis Pipeline Analysis:
The Primary Sclerosing Cholangitis pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies
Primary Sclerosing Cholangitis Pipeline Market Drivers
Primary Sclerosing Cholangitis Pipeline Market Barriers
Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight
Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials
Table of Contents
1
Primary Sclerosing Cholangitis Report Introduction
2
Primary Sclerosing Cholangitis Executive Summary
3
4
Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment
5
Primary Sclerosing Cholangitis Pipeline Therapeutics
6
Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)
7
Primary Sclerosing Cholangitis Mid Stage Products (Phase II)
8
Primary Sclerosing Cholangitis Early Stage Products (Phase I)
9
Primary Sclerosing Cholangitis Preclinical Stage Products
10
Primary Sclerosing Cholangitis Therapeutics Assessment
11
Primary Sclerosing Cholangitis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Primary Sclerosing Cholangitis Key Companies
14
Primary Sclerosing Cholangitis Key Products
15
Primary Sclerosing Cholangitis Unmet Needs
16
Primary Sclerosing Cholangitis Market Drivers and Barriers
17
Primary Sclerosing Cholangitis Future Perspectives and Conclusion
18
Primary Sclerosing Cholangitis Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting